Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elobixibat - Albireo Pharma/EA Pharma

Drug Profile

Elobixibat - Albireo Pharma/EA Pharma

Alternative Names: A-3309; AJG-533; Goofice

Latest Information Update: 15 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Albireo Pharma; EA Pharma; Mochida Pharmaceutical
  • Class 2 ring heterocyclic compounds; Amides; Carboxylic acids; Hepatoprotectants; Laxatives; Small molecules; Sulfides; Sulfones; Thiazepines
  • Mechanism of Action Sodium-bile acid cotransporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation
  • Phase II Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Discontinued Dyslipidaemias; Irritable bowel syndrome

Most Recent Events

  • 11 Apr 2019 Albireo Pharma plans a phase II trial for Non-alcoholic steatohepatitis and Non-alcoholic fatty liver disease in the second quarter of 2019
  • 11 Apr 2019 US FDA approves IND application for elobixibat in Non-alcoholic fatty liver disease and Non-alcoholic steatohepatitis
  • 07 Aug 2018 Albireo Pharma has patent protection for elobixibat in USA and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top